ミシシッピ州における肥満症の臨床試験
ミシシッピ州内の拠点で、肥満症に関する15件の研究が参加者を募集しています。
ミシシッピ州内の都市
公式研究テキスト（英語）
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Olive Branch Family Medical Center, Olive Branch
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07783802A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Dynamed Clinical Research, LP d/b/a DM Clinical Research, Gulfport
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/24更新 · NCT06672549A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Fayette
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Jackson Heart Clinic, Jackson
- Cardiology Associates of North Mississippi, Tupelo
被験者募集中第3相
45歳〜99歳 · 全性別 · 2026/09/22更新 · NCT07037433A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Gulfport
- AURORA-1 Clinical Site, Jackson
- AURORA-1 Clinical Site, Olive Branch
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Gulfport
- AURORA-2 Clinical Site, Jackson
- AURORA-2 Clinical Site, Olive Branch
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Olive Branch Family Medical Center, Olive Branch
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- DelRicht Research at Gulfport Memorial, Gulfport
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Gulfport
- ACCOMPLISH-2 Research Site, Ridgeland
被験者募集中第3相健康なボランティア歓迎
18歳〜79歳 · 全性別 · 2026/09/11更新 · NCT07654374Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Prime Health and Wellness Sky Clinical Research Network Group, Fayette
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Sky Integrative Medical Center, Ridgeland
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/08/27更新 · NCT07575399A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Hawthorne Health, Diamondhead
- Univ of Mississippi Med Center, Jackson
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Gulfport
- ACCOMPLISH-1 Research Site, Ridgeland
被験者募集中第3相
18歳〜79歳 · 全性別 · 2026/08/10更新 · NCT07654361The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
- University of Mississippi Medical Center, Jackson
被験者募集中観察研究健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2025/07/04更新 · NCT07052539Time-restricted Eating Acceptability, Efficacy and Safety in Obesity
- Department of Nutrition and Hospitality Management, University of Mississippi, Oxford
被験者募集中健康なボランティア歓迎
19歳〜65歳 · 全性別 · 2024/12/06更新 · NCT06695988ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。